Brief: Glenmark Pharma Approves Transfer Of Nebulizer Brands/Ip Portfolio To Unit
29/05/2026 16:32
BRIEF-Glenmark Pharma Approves Transfer Of Nebulizer Brands/Ip Portfolio To Unit May 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
APPROVES TRANSFER OF NEBULIZER BRANDS/IP PORTFOLIO TO UNIT
Source text: [ID:]
Further company coverage: GLEN.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter